SCHEDULE: Allurion Secures $3.1M, Restructures Debt with RTW

Allurion Technologies, Inc. announced a debt-for-equity exchange and a private placement, strengthening its financial position and governance with RTW Investments.

Summary

• RTW Funds exchanged existing debt obligations, including remaining principal and accrued interest of Notes, $48.0 million from the First RIFA, and $9.5 million from the Second RIFA, for newly designated Series B convertible preferred stock.
• The Series B Preferred Stock has an initial stated value of $1,000 per share, a conversion price of $3.37, and accrues dividends at 8.25% per annum, payable in cash or by increasing accrued value.
• RTW Funds participated in a private placement, purchasing 1,856,288 shares of Common Stock and accompanying warrants for approximately $3.1 million at a purchase price of $1.67 per share.
• RTW Investments, LP and Roderick Wong now beneficially own 5,891,430 shares, representing 48.1% of Allurion's common stock, based on 12,249,232 shares outstanding post-private placement.
• New governance rights grant RTW the ability to nominate directors based on their ownership stake, with potential for additional nominations upon a 'Specified Breach Event' related to cash balance or FDA marketing authorization.

Sentiment

Score: 6

Explanation: The filing indicates a significant financial restructuring and capital injection from a key investor, which is positive for stability. However, the terms involve substantial potential dilution and strict governance conditions tied to critical operational milestones (FDA approval, cash balance), suggesting the company faces significant challenges and investor oversight.

Positives

• The debt restructuring through the Note and RIFA Exchange converts existing obligations into Series B Preferred Stock, potentially reducing immediate cash outflow for debt service and improving the balance sheet.
• The Private Placement raised approximately $3.1 million in new capital for the company, providing additional liquidity.
• RTW Investments, a significant institutional investor, is deepening its commitment to Allurion Technologies, indicating continued confidence in the company's long-term prospects.
• The Series B Preferred Stock ranks senior to all other capital stock for dividends, distributions, and liquidation, offering a strong preference to RTW.

Negatives

• The issuance of Series B Preferred Stock and warrants, along with their potential conversion into common stock, could lead to significant dilution for existing common stockholders.
• The 8.25% dividend rate on Series B Preferred Stock, even if initially paid by increasing accrued value, represents a substantial future financial obligation.
• The 'Specified Breach Event' conditions (maintaining a minimum $3.0 million unrestricted cash balance and obtaining FDA marketing authorization by December 31, 2026) highlight critical operational and regulatory hurdles that, if not met, could trigger increased RTW governance influence and a higher dividend rate.

Risks

• Failure to obtain stockholder approval for the issuance of Series B Preferred Stock and Common Stock issuable upon conversion by January 31, 2026, could jeopardize the Exchange agreement.
• Failure to obtain stockholder approval for the issuance of shares upon exercise of Private Placement Warrants could impact the warrant holders' ability to convert.
• The company must maintain a minimum aggregate balance of $3.0 million in unrestricted cash to avoid a 'Specified Breach Event'.
• The company must obtain a marketing authorization from the U.S. Food and Drug Administration for one of its products no later than December 31, 2026, to avoid a 'Specified Breach Event'.
• Potential for significant dilution from the conversion of Series B Preferred Stock and exercise of Private Placement Warrants.
• The beneficial ownership limitation (9.9%) on Series B Preferred Stock conversion and warrant exercise could restrict RTW's ability to fully convert their holdings into common stock immediately.

Future Outlook

The company is working towards obtaining stockholder approval for the Series B Preferred Stock and warrant issuances by January 31, 2026, and aims to secure FDA marketing authorization for one of its products by December 31, 2026. It also plans to file resale registration statements for the newly issued securities by January 10, 2026, with an aim for effectiveness within 90-120 days.

Industry Context

This filing indicates a life sciences or medical device company (given the FDA authorization requirement) that is undergoing significant financial restructuring and capital infusion from a specialized healthcare investor. The reliance on preferred stock and warrants suggests a company in a growth or turnaround phase, seeking to manage debt and secure funding for future milestones like regulatory approvals.

Corporate Governance

Related Party Transactions

• RTW Funds (the reporting persons) are exchanging existing debt obligations with Allurion Technologies, Inc. for Series B convertible preferred stock.
• RTW Funds also participated as accredited investors in the Private Placement, purchasing Common Stock and warrants from Allurion Technologies, Inc.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the conversion of Series B Preferred Stock and exercise of warrants. The restructuring aims to improve the company's financial stability, which could benefit long-term shareholders.
• Creditors: Existing debt obligations are being converted into preferred equity, which could improve the company's debt-to-equity ratio and reduce immediate debt service requirements.
• Management/Board: Increased oversight and influence from RTW Investments through new director nomination rights, especially if performance milestones are not met.

Next Steps

• Obtain stockholder approval for the issuance of Series B Preferred Stock and Common Stock issuable upon conversion by January 31, 2026.
• File a Certificate of Designations of Rights and Preferences of the Series B Preferred Stock with the Secretary of State of Delaware.
• Ensure compliance with listing requirements and obtain approval for listing of Conversion Shares on the national securities exchange.
• Hold a meeting of stockholders by January 31, 2026, to obtain approval for the issuance of shares upon exercise of Private Placement Warrants.
• File a resale registration statement with the SEC for Private Placement Securities by January 10, 2026, and aim for effectiveness within 90-120 days.
• Work towards obtaining FDA marketing authorization for one of its products by December 31, 2026.

Key Dates

Recommendation

The company is undergoing a critical financial restructuring and has secured additional capital from a major investor, RTW Investments. This provides necessary funding and converts existing debt into preferred equity, which can improve the balance sheet. However, the terms involve significant potential dilution for common shareholders, a substantial dividend obligation on the preferred stock, and stringent governance conditions tied to key operational milestones, particularly FDA approval by December 2026. While the capital infusion is positive, the underlying risks and the complexity of the preferred stock structure suggest a 'hold' recommendation, advising investors to monitor the company's progress on its milestones and the impact of potential dilution before making further investment decisions.

Keywords

Allurion Technologies, RTW Investments, Schedule 13D, Debt Restructuring, Private Placement, Series B Preferred Stock, Convertible Preferred Stock, Warrants, Corporate Governance, FDA Authorization, Capital Raise, Shareholder Ownership, Dilution